Latest Breaking News On - Business portfolio development - Page 1 : comparemela.com

SIFI Announces the Granting of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis

/PRNewswire/ SIFI S.p.A. ("SIFI" or the "Company"), a leading international ophthalmic pharmaceutical company, announced today that the U.S. Food and Drug.

United statesEdward hollandSebastiano giuffridaMaria grazia mazzoneJelle kleijnBusiness portfolio developmentHead of clinical developmentUniversity of cincinnatiEuropean medicines agencyDrug administrationResearch developmentOrphan drug designationExecutive directorPortfolio developmentDrug designationPrescription drug user fee act

SIFI Announces the Granting of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis

SIFI Announces the Granting of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis
laragione.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from laragione.eu Daily Mail and Mail on Sunday newspapers.

United statesEdward hollandMaria grazia mazzoneBusiness portfolio developmentSebastiano giuffridahead of clinical developmentUniversity of cincinnatiEuropean medicines agencyDrug administrationResearch developmentAcanthamoeba keratitisOrphan drug designationExecutive directorPortfolio developmentDrug designationPrescription drug user fee actMarketing authorisation application

SIFI SpA: SIFI Announces the Granting of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis

This follows the previously granted ODD for polihexanide in Acanthamoeba Keratitis by the FDA and EMA. An estimated 15,660 patients with fungal keratitis are diagnosed annually in the

United statesKostenloser wertpapierhandelEdward hollandSebastiano giuffridaMaria grazia mazzoneJelle kleijnBusiness portfolio developmentHead of clinical developmentUniversity of cincinnatiEuropean medicines agencyDrug administrationResearch developmentAcanthamoeba keratitisOrphan drug designationExecutive directorPortfolio development

SIFI Announces the Granting of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesEdward hollandSebastiano giuffridaMaria grazia mazzoneJelle kleijnBusiness portfolio developmentHead of clinical developmentUniversity of cincinnatiEuropean medicines agencyDrug administrationResearch developmentOrphan drug designationExecutive directorPortfolio developmentDrug designationPrescription drug user fee act

SIFI Announces the Granting of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis

/CNW/ SIFI S.p.A. ("SIFI" or the "Company"), a leading international ophthalmic pharmaceutical company, announced today that the U.S. Food and Drug.

United statesEdward hollandSebastiano giuffridaMaria grazia mazzoneJelle kleijnBusiness portfolio developmentHead of clinical developmentUniversity of cincinnatiEuropean medicines agencyDrug administrationResearch developmentOrphan drug designationExecutive directorPortfolio developmentDrug designationPrescription drug user fee act